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OBJECTIVES The purpose of this study was to prospectively investigate the effects of surgical correction of
mitral regurgitation (MR) on exercise performance, cardiac function and neurohormonal
activation.
BACKGROUND Little is known about the effect of surgical correction of MR on functional status or on
neurohormonal activation.
METHODS Cardiopulmonary exercise test, radionuclide angiography and blood samples for assessment of
neurohormonal status were obtained in 40 patients with nonischemic MR before and within
one year (216 6 80 days) after surgery. Twenty-four patients underwent mitral valve repair
(MVr), and 16 underwent valve replacement (VR) with anterior chordal transection.
RESULTS Despite an improvement in New York Heart Association functional class, exercise perfor-
mance did not change (peak oxygen consumption: 19.3 6 6.1 to 18.5 6 5.6 ml/kg/min,
percentage of maximal predicted oxygen consumption: 79.5 6 18.2% to 76.8 6 16.9%). After
surgery, left ventricular (LV) ejection fraction (EF) decreased (64.2 6 10.3% to 59.9 6
11.4%, p 5 0.003) while right ventricular (RV) EF increased (41.4 6 9.6% to 44.7 6 9.5%,
p 5 0.03). Left ventricular EF did not change after MVr (64.3 6 11.5% to 61.5 6 12.2%),
but RVEF improved (40.4 6 9.2% to 46.0 6 10.0%, p 5 0.02). In contrast, VR was
associated with an impairment of LV function in the apicolateral area and a decrease in LVEF
(64.1 6 8.5% to 57.4 6 10.0%, p 5 0.01), whereas RVEF did not change (42.9 6 10.3% to
42.8 6 8.6%). Moreover, there was only a slight decrease in neurohormonal activation after
surgery.
CONCLUSIONS Despite an improvement in symptomatic status, exercise performance was not improved seven
months after either MVr or VR for MR, and neurohormonal activation persisted. Compared
with MVr, VR resulted in a significant impairment of cardiac function in this study. (J Am
Coll Cardiol 2000;36:2263–9) © 2000 by the American College of Cardiology
Surgical correction of mitral regurgitation (MR) aims to
preserve cardiac function and to improve functional status
and survival (1,2). Chronic MR results in a progressive
deterioration in left ventricular (LV) contractile function
(3,4) although the LV ejection fraction (EF) is maintained
over a relatively long period. However, recent data in an
animal model of MR (5), as well as in humans with chronic
MR (1), suggest that LV contractile impairment recovers
toward normal in most patients after mitral valve surgery.
Although exercise capacity is an important parameter of
quality of life, there is limited information regarding the
effect of mitral valve surgery on exercise capacity (6–13),
particularly in patients with MR (7–11). Moreover, whether
preservation of LV function after mitral valve surgery results
in an improvement of exercise capacity is unknown. Periph-
eral factors are important determinants of exercise perfor-
mance for patients with heart failure (14–17). Patients with
heart failure have neurohormonal activation, which may
contribute to impairment of exercise performance by limit-
ing exercise-induced vasodilatation or by contributing to
maldistribution of peripheral blood flow. However, the
effect of mitral valve surgery for severe MR on neurohor-
monal status is unknown.
Therefore, the purpose of this study was to assess the
effects of mitral valve surgery on cardiac function, exer-
cise performance with measurement of gas exchange and
neurohormonal activation for patients with pure isolated
nonischemic MR.
METHODS
Study patients. Forty consecutive patients who underwent
successful mitral valve surgery for pure chronic nonischemic
MR were studied. Patients were excluded from the study if
they had significant pulmonary or coronary disease, other
significant valve disease apart from tricuspid regurgitation,
previous thoracic surgery or intermittent claudication severe
enough to interfere with the performance of exercise testing.
All patients had moderately severe (grade 3, 30 patients) or
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severe (grade 4, 10 patients) MR for at least six months. All
patients gave informed consent, and the study protocol was
approved by the Ethics Committee of the University.
Surgery. The decision regarding the type of corrective
surgery was made by the cardiovascular surgeon on the basis
of preoperative data and after assessment of the anatomic
status of the mitral valve during surgery. Sixteen patients
(40%) underwent mitral valve replacement (VR) with pos-
terior chordal preservation and anterior chordal resection.
St. Jude prosthetic valves were used in 14 patients and
bioprosthetic valves (Carpentier-Edwards) in the remaining
two patients. Twenty-four patients (60%) underwent mitral
valve repair (MVr) using the technique described by Car-
pentier et al. (18). No patient had significant residual MR
after surgery.
Radionuclide angiography. All patients underwent radio-
nuclide angiography, cardiopulmonary exercise testing and
blood sampling for assessment of neurohormonal status
before and within one year (216 6 80 days) after surgery.
Radionuclide angiography was performed at rest in the
supine position using red blood cells labeled in vivo with
20 mCi of technetium-99m. Data were acquired in the left
anterior oblique view at 45° and 70° by means of a gamma
camera (DST camera, Sopha Medical, data processing
Sophy). All studies were formatted at 16 frames per cardiac
cycle. RR intervals and heart rate (beats/min) were re-
corded. Cardiac cycles with RR intervals that were not
within 20% of the average value were discarded. Left
ventricle and right ventricle (RV) EF were determined using
the equilibrium technique by automated detection of end
diastolic and end systolic contours, with manual correction
if necessary. The LV was divided into nine regions to
analyze regional EF in the left anterior oblique view at 45°.
Regions 1 and 9 correspond to the base of heart, regions 2
and 3 to the posterolateral region, 4, 5 and 6 to the lateral,
apical and anteroapical region, respectively, 7 and 8 to the
anteroseptal and septal region. All radionuclide angiograma
was performed by the same investigator (C.F.) who was not
aware of the type of surgery performed.
Cardiopulmonary exercise test. Exercise tests were per-
formed in the morning after a light standard meal on an
upright electromagnetically braked bicycle (Ergo-metrics
900, Ergoline GmbH, Bitz, Germany) using a continuous
protocol (10 W/min). Beta-adrenergic blocking agents were
withdrawn 48 h before exercise. Others medications were
continued. Patients were asked to cycle at a constant rate of
60 revolutions per minute. Patients were allowed to con-
tinue until the respiratory exchange ratio (defined as the
ratio between oxygen consumption and carbon dioxide
production) was 1. Exercise was terminated at the point
when the patient was unable to continue due to fatigue or
dyspnea. Heart rate was continuously recorded on a 12-lead
electrocardiogram (Case 15, Marquette Electronics Inc.,
Milwaukee, Wisconsin). Blood pressure was measured every
2 min and at peak exercise with a mercury sphygmomanom-
eter. The data for gas exchange were collected on a
breath-by-breath basis using a permanent zirconium oxide
electrochemical cell, and the carbon dioxide fraction was
measured by using a dual-beam infrared absorption cham-
ber (CPX system, Medical Graphics Corporation, St. Paul,
Minnesota). Both analyzers were calibrated by using stan-
dard gas mixtures before each exercise test. Anaerobic
threshold was determined by the V slope method and by
analyzing the ratio of minute ventilation against oxygen
consumption (VO2) and the ratio of minute ventilation
against carbon dioxide production. Peak VO2 and peak
carbon dioxide production were defined as the highest value
obtained during the last 2 min of exercise. Predicted value of
maximal oxygen consumption (PVO2) was calculated with
use of the Wasserman equation, normalizing maximal VO2
for age, gender, weight and height (19).
As a preoperative, LVEF $60% is associated with an
excellent outcome after surgery and the preservation of
postoperative LVEF (20,21), patients were divided into two
subgroups according to their preoperative LVEF (,60%
and $60%), and the effect of mitral valve surgery on exercise
performance was determined in each subgroup. To evaluate
the effect of medications on exercise capacity and LV
function, patients were also classified according to their
postoperative medication status (unchanged or decreased).
Neurohormonal measurements. Blood samples were ob-
tained at rest from a peripheral vein from patients and
controls subjects (n 5 24). Blood for norepinephrine was
collected into heparinized tubes. Samples were collected
into chilled tubes containing EDTA for measurement of
plasma renin activity (PRA) and aldosterone and into
chilled tubes containing EDTA and aprotinin for measure-
ment of plasma levels of atrial natriuretic peptide (ANP)
and of endothelin-1. Samples were kept on ice and centri-
fuged at 4°C within 30 min. All separated plasma samples
were stored at 270°C until analysis. Plasma norepinephrine
concentrations were measured by high performance liquid
chromatography. The normal range was 100 to 600 pg/ml.
Plasma renin activity was determined by estimation of the
rate of generation of angiotensin I in plasma by radio-
immunoassay. The normal range was 0.5 to 3 ng/ml per h.
Plasma aldosterone concentrations were measured by radio-
immunoassay using a commercially available kit (Behring,
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
EF 5 ejection fraction
LV 5 left ventricle
MR 5 mitral regurgitation
MVr 5 mitral valve repair
NYHA 5 New York Heart Association
PRA 5 plasma renin activity
PVO2 5 predicted value of maximal oxygen
consumption
RV 5 right ventricle
VO2 5 oxygen consumption
VR 5 mitral valve replacement
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France). The normal range was 10 to 160 pg/ml. Plasma
ANP and endothelin-1 concentrations were measured by
radioimmunoassay after extraction on a Sep-Pak C-18
cartridge using a commercially available kit (Nichols Insti-
tute Diagnostics BV, the Netherlands). For determination
of plasma endothelin concentrations, the assay was cali-
brated with endothelin-1. According to the manufacturer,
the cross-reactivities to endothelin-2 and endothelin-3 were
52% and 96%, respectively, and the cross-reactivity to
big-endothelin was 7%. The normal range of ANP was 5 to
25 pmol/l, and the normal range of endothelin-1 was 1.1 to
2.3 pmol/l.
Statistics. Results are expressed as mean 6 standard devi-
ation and as median (95% confidence interval) for neuro-
hormonal values. Comparisons between groups were per-
formed with chi-square tests or with paired or unpaired
Student t tests, as appropriate. Nonparametric tests (Mann-
Whitney U and Wilcoxon) were used to compare hormone
levels. Comparison of exercise parameters between preop-
erative and postoperative groups was performed with use of
a two-way repeated-measures analysis of variance. The
interaction between time and operations were tested. A p
value #0.05 was considered statistically significant.
RESULTS
Clinical data. Ten patients were in New York Heart
Association (NYHA) functional class I (25%), 20 in class II
(50%) and 10 in class III (25%) before surgery. Patients were
more symptomatic before (mean NYHA class: 2.00 6 0.72)
than after operation (1.35 6 0.53, p , 0.001). Ten patients
were in atrial fibrillation before surgery and seven patients
after surgery.
Table 1 gives the baseline characteristics of the two
groups of patients. Patients who underwent VR were older
than those who underwent MVr (p 5 0.007) and were more
symptomatic before (p 5 0.02), but not after, surgery.
Myxomatous degeneration was the most frequent etiology
of MR in the MVr group, whereas rheumatic disease was
more frequent in the VR group. Aortic cross-clamp time
and total cardiopulmonary bypass time were, respectively,
87 6 29 min and 106 6 32 min in the MVr group
compared with 57 6 27 min (p 5 0.002) and 70 6 24 min
(p , 0.001) in the VR group.
Radionuclide angiography. Baseline RV and LV function
were similar in the two patient groups (Fig. 1). After surgery
LVEF decreased significantly from 64.2 6 10.3% to 59.9 6
11.4% (p 5 0.003), whereas RVEF increased from 41.4 6
9.6% to 44.7 6 9.5% (p 5 0.03). Mitral valve repair was
associated with a significant increase in RVEF (p 5 0.02),
whereas LVEF did not change significantly. In contrast,
patients who underwent VR had a significant decrease in
LVEF (p 5 0.01), whereas RVEF was unchanged. More-
over, there was a significant decrease (p , 0.05) in regional
EF 4 and 5 (Fig. 2) of the LV after VR compared with
MVr.
Cardiopulmonary exercise test. Despite correction of
MR, there was no overall improvement in peak VO2
(19.3 6 6.1 ml/min/kg to 18.5 6 5.6 ml/min/kg) or
percentage of PVO2 (percentage of PVO2, 79.5 6 18.2 to
Figure 1. Changes in LV and RV ejection fraction according to the type of
corrective surgery performed. LV 5 left ventricle; RV 5 right ventricle.
Figure 2. Analysis of regional ejection fraction of the left ventricle: there is
a significant decrease in regional ejection fraction after mitral valve
replacement in the regions 4 and 5 (apicolateral area) compared with mitral
valve repair (p , 0.05).
Table 1. Baseline Characteristics in Patients Undergoing
Mitral Valve Replacement and Patients Undergoing Mitral
Valve Repair
Mitral Valve
Replacement
Mitral Valve
Repair
p
Value
n 16 24
Men/Women 8/8 16/8 NS
Age (yrs) 65 6 7 55 6 13 0.007
NYHA functional class 2.31 6 0.70 1.79 6 0.66 0.02
Atrial fibrillation 6 (38%) 4 (17%) NS
Etiology
Myxomatous degeneration 8 19
Rheumatic disease 5 1 0.05
Bacterial endocarditis 3 4
Treatment
Diuretics 12 11
Digoxin 9 11 NS
ACE inhibitors 14 12
Beta-blockers 1 3
ACE inhibitors 5 angiotensin converting enzyme inhibitors; NYHA 5 New York
Heart Association.
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76.8 6 16.9) after surgery in all patients, as well as in either
the valve repair or the valve replacement group (Table 2).
Indeed, there was a slight but significant decrease in mean
exercise time (600 6 247 s to 544 6 204 s, p 5 0.02). This
decrease in exercise duration was similar in both groups.
There was no difference before or after surgery between
groups in maximal exercise tolerance assessed by peak O2
pulse or by percentage of PVO2. Using two-way repeated-
measures analysis of variance, we found no interaction
between time and operation type on exercise capacity.
Moreover, there was no difference between patients classi-
fied according to preoperative LVEF (,60% in 14 patients
and $60% in 26 patients) with respect to postoperative
percentage PVO2 (74.2 6 16.5% vs. 77.1 6 17.7%) or peak
VO2 (18.1 6 6.9 ml/kg/min vs. 18.1 6 4.7 ml/kg/min).
Nor was there any difference in postoperative exercise
performance when the patients were divided into two
subgroups based on median postoperative LVEF (,60%
and $60%).
Effect of medication on cardiac function and exercise
tolerance. There was no significant difference in number of
drugs prescribed between groups (repair or replacement) before
or after surgery. However, there was a significant decrease in
the number of drugs prescribed after surgery (p 5 0.02). Fewer
patients were taking diuretics (13 vs. 23 patients), digoxin (14
vs. 20 patients) or angiotensin-converting enzyme inhibitors
(13 vs. 26 patients), whereas more were taking beta-blockers
(14 vs. 4 patients). We divided the whole population into two
subgroups as a function of treatment modification (withdrawal
of at least one drug compared with no modification). In the
subgroup of patients without treatment modification (n 5 18),
peak VO2 significantly decreased (19.4 6 7.1 ml/kg/min to
17.1 6 5.2 ml/kg/min, p 5 0.04), but this decrease was not
significant in the percentage of PVO2 (80.8 6 22.5% to
73.6 6 17.6%) or in the absolute value of VO2 max (1,328 6
468 ml/kg to 1,209 6 408 ml/kg). In the second subgroup of
patients (n 5 22), withdrawal of one or more drug had no
effect on exercise capacity, suggesting that treatment status had
a marginal effect or no effect on exercise capacity in our
population. Moreover, we did not find any effect of treatment
modification on LV and RVEF, with a similar decrease in
LVEF and a similar increase in RVEF after surgery.
Neurohormonal activation. The results of preoperative
and postoperative neurohormonal measurements are pre-
sented in Table 3, in conjunction with measurements in
control subjects. There was a slight decrease in neurohor-
monal activation after surgery. The decrease in PRA and in
plasma aldosterone levels is probably related to the with-
drawal of angiotensin-converting enzyme inhibitors and
diuretics after surgery. Plasma levels of ANP decreased after
surgery (p 5 0.03); however, all but one patient had
persistently high concentrations of ANP (.25 pmol/l).
Moreover, norepinephrine, PRA, aldosterone and ANP
measurements were significantly higher than they were in
control subjects both before and after surgery. No significant
Table 2. Effect of Surgery on Exercise Parameters in Patients Undergoing Mitral Valve
Replacement and Patients Undergoing Mitral Valve Repair
Mitral Valve Repair
(n 5 24)
Mitral Valve Replacement
(n 5 16)
Before After Before After
Duration of exercise(s) 678 6 246 605 6 204* 483 6 202 452 6 172*
Peak VO2 (ml/min) 1,513 6 461 1,408 6 438 1,169 6 392 1,201 6 381
Peak VO2 (ml/kg/min) 21.5 6 6.1 19.9 6 5.9 16.1 6 4.5 16.2 6 4.3
% PVO2 82.0 6 17.2 76.5 6 16.6 75.7 6 19.5 76.9 6 17.9
Peak O2 pulse (ml/min/beat) 9.5 6 3.0 9.3 6 2.1 9.2 6 3.8 9.2 6 3.2
% of predicted value of
maximal heart rate
98 6 10 91 6 11 85 6 15 86 6 14
Peak VE (l/min) 62.5 6 19.1 58.2 6 17.6 55.9 6 16.5 54.2 6 13.3
*p , 0.05 after surgery versus before surgery.
peak O2 pulse 5 peak oxygen pulse; peak VE 5 peak minute ventilation; % PVO2 5 percentage of predicted value of
maximal oxygen consumption; VO2 5 oxygen consumption.
Table 3. Neurohormone Levels Before and After Surgery
Before After
Controls
(n 5 24)
Norepinephrine (pg/l) 520 (400–650)† 430 (380–610)† 130 (100–260)
PRA (ng/ml/h) 3.1 (2.0–4.5)† 1.2 (0.9–2.2)*† 0.88 (0.56–1.22)
Aldosterone (pg/ml) 160 (118–180)† 93 (58–133)*† 78 (49–107)
ANP (pmol/l) 75 (47–128)† 62 (48–79)*† 14 (8–21)
Endothelin-1 (pmol/l) 2.1 (1.9–2.4)† 1.8 (1.6–2.2) 1.7 (1.2–2.1)
Data presented are median value (95% confidence interval). *p , 0.05 after vs. before; †p , 0.01 vs. control.
ANP 5 atrial natriuretic peptide; PRA 5 plasma renin activity.
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difference was observed between the patients who had VR
and those who had MVr.
DISCUSSION
The purpose of this study was to determine whether
successful mitral valve surgery for chronic MR affected
exercise performance, ventricular EF or neurohormonal
activation. The major, and somewhat unexpected, finding of
the study was that exercise performance, assessed by cardio-
pulmonary exercise testing, was unchanged after surgery
despite a significant improvement in NYHA functional
status. Although MVr preserved cardiac function while VR
resulted in a significant impairment of LV and RV function,
exercise performance was not improved after either MVr or
VR. Moreover, there was only a slight decrease in neuro-
hormonal activation after surgery in our patients. This study
also demonstrates the deleterious effect of anterior chordal
transection during VR, which resulted in a significant
impairment of regional LVEF in the area of chordal
insertion.
Exercise capacity. To our knowledge, this is the first
prospectively designed study that investigated exercise per-
formance with a cardiopulmonary exercise test before and
after either MVr or VR for pure chronic MR. There was
previously only limited information regarding the effect of
heart surgery on exercise capacity (6–13,22) and particularly
the effect of mitral valve surgery in patients with chronic
MR (7–11). Previous studies had small numbers of patients,
with diverse cardiac pathology. In one study (22), myocar-
dial revascularization was associated with an increase in
work capacity after intensive cardiac rehabilitation. How-
ever, VO2 was not measured and angina pectoris limited the
preoperative exercise capacity. Most of the patients with
valvular heart disease were in atrial fibrillation before sur-
gery, and postoperative exercise capacity improvement may
well have been related to conversion to sinus rhythm (8,9).
Several studies reported a significant lower postoperative
exercise capacity for patients undergoing mitral valve sur-
gery (particularly after VR) compared with patients under-
going aortic valve surgery (6,10,12). Although individual
variations were observed in our study, patients did not have
an increase in peak VO2 or percentage of PVO2 seven
months after surgery despite a significant improvement in
NYHA functional class. In contrast with a previous study
performed in a rehabilitation center without assessment of
VO2 (10), we found no improvement in either exercise
duration or in peak workload. Indeed, mean exercise time
decreased slightly but significantly after surgery (600 6
247 s to 544 6 204 s, p 5 0.02). However, exercise time is
a less accurate parameter than VO2 to assess objective
exercise capacity. Moreover, our results indicate that exer-
cise performance did not improve after either MVr or VR
for severe MR (Table 2).
Determinants of exercise capacity. There was no differ-
ence regarding peak VO2 or percentage of PVO2 between
patients with preoperative or postoperative LVEF values of
more than 60% or less than 60%. Based on these results, LV
function assessed by LVEF does not appear to be an
important determinant of exercise capacity for patients with
MR. Indeed, previous studies have demonstrated that peak
VO2 correlates weakly with LVEF in heart failure, leading
to the general recognition that systolic function is not a key
determinant of exercise capacity (23,24).
Diastolic dysfunction can lead to symptomatic heart
failure despite normal systolic function (25). Thus, it is
possible that persistent impairment of diastolic function
limited the improvement in exercise capacity in our study.
Indeed, despite normal postoperative value of peak filling
rate, time to peak filling rate (assessed by radionuclide
angiography) was slightly increased after surgery compared
with normal patients (data not shown).
Pulmonary and peripheral factors may be of particular
importance for patients with heart failure (14–17). Patients
with heart failure develop skeletal muscle changes (15) and
alteration of blood flow distribution (14,16). After cardiac
surgery, there is likely to be additional muscle decondition-
ing and further impairment of lung dysfunction. After heart
transplantation, the reversal of skeletal muscle abnormalities
or of impaired vasodilatation is delayed for more than a year
(26,27) and may contribute to the observed reduction in
exercise capacity. Nakamura et al. (7) and Chiba et al. (8)
reported in 11 and 23 patients, respectively, a significant
correlation between the improvement in vascular function
(endothelium-dependent peripheral vasorelaxation) and
changes in peak VO2 several months after mitral or aortic
valve surgery.
Neurohormonal activation. Neurohormonal activation
may contribute to the impairment of exercise performance
in patients with heart failure by limiting exercise-induced
vasodilatation or by contributing to maldistribution of
peripheral blood flow. In the study of Nakamura et al. (7),
the improvement in exercise capacity was associated with an
important decrease in plasma ANP levels (167 to 41 pg/ml,
with a normal range of 5 to 45 pg/ml). Left ventricular
dysfunction is considered to be the main determinant of
neurohormonal activation. Indeed, Starling’s research on
MR (unpublished data) demonstrated a strong inverse
correlation between plasma norepinephrine levels and LV
contractility (r 5 20.91) in patients with MR. The persis-
tent neurohormonal activation in this study probably reflects
incomplete recovery of LV contractility seven months after
surgery. Recent data in an animal model of MR (5) as well
as in humans with chronic MR (1) indicate that LV
contractile impairment recovers toward normal in most
patients after mitral valve surgery despite the decrease in
LVEF (2,28,29). Data concerning the timing of recovery of
LV function after surgery are conflicting, requiring one to
three years. However, patients in this study were evaluated
at an average of seven months (216 6 80 days) after surgery,
which is consistent with an incomplete recovery of LV
contractility.
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Ventricular function. This study also demonstrates the
deleterious effect of anterior chordal resection on cardiac
function. Despite preservation of the posterior chordae
tendinae, anterior chordal transection during VR was asso-
ciated with a significant impairment of LV regional EF in
the area of anterior papillary muscle insertion and a signif-
icant decrease in LVEF in this study. This result is
consistent with previous studies that indicate that preserva-
tion of the mitral valve apparatus during mitral valve surgery
for MR improves postoperative LV function (29–35).
Impairment of LV regional function after chordal transec-
tion has been described previously (29,31,35). We, thus,
believe that the significant postoperative differences we
observed in ventricular function were likely due, in part, to
anterior chordal transection. Moreover, our data demon-
strates that RVEF was unchanged after VR but increased
after MVr.
Study limitations. First, the lack of randomization be-
tween the two types of surgery is the main limitation of this
study. The decision regarding the choice of corrective
surgery was made by the cardiovascular surgeon on the basis
of preoperative data and after assessment of the anatomic
status of the mitral valve during surgery. However, since it
is well established that MVr is the operation of choice for
mitral valve disease (2,21,34), a randomized control trial
may no longer be considered ethical. However, the two
patients groups (MVr or VR) were similar with respect to
preoperative radionuclide angiographic variables, exercise
capacity and neurohormonal activation. There were only
slight differences concerning age, etiology of MR and
subjective functional capacity assessed with the NYHA
classification. Second, it is possible that the lack of improve-
ment in exercise capacity in this study was related to the
relatively short-term follow-up period. Longer follow-up
will be necessary to assess exercise performance two to three
years after surgery.
Conclusions. In summary, the results of this prospective
study indicate that exercise performance does not improve
in most patients within one year of mitral valve surgery for
severe chronic MR. The persistent impairment of exercise
capacity does not appear to be related to LVEF or to the
type of corrective surgery performed. The modest regression
of neurohormonal activation in this study may contribute to
the impaired exercise capacity. Finally, anterior chordal
transsection resulted in a significant impairment of regional
and global LVEF.
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